Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and ster...
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy
About this item
Full title
Author / Creator
Schaule, Jana , Kroeze, Stephanie G. C , Blanck, Oliver , Stera, Susanne , Kahl, Klaus H , Roeder, Falk , Combs, Stephanie E , Kaul, David , Claes, An , Schymalla, Markus M , Adebahr, Sonja , Eckert, Franziska , Lohaus, Fabian , Abbasi-Senger, Nasrin , Henke, Guido , Szuecs, Marcella , Geier, Michael , Sundahl, Nora , Buergy, Daniel , Dummer, Reinhard and Guckenberger, Matthias
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Melanoma patients frequently develop brain metastases. The most widely used score to predict survival is the molGPA based on a mixed treatment of stereotactic radiotherapy (SRT) and whole brain radiotherapy (WBRT). In addition, systemic therapy was not considered. We therefore aimed to evaluate the performance of the molGPA score in pati...
Alternative Titles
Full title
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy
Authors, Artists and Contributors
Author / Creator
Kroeze, Stephanie G. C
Blanck, Oliver
Stera, Susanne
Kahl, Klaus H
Roeder, Falk
Combs, Stephanie E
Kaul, David
Claes, An
Schymalla, Markus M
Adebahr, Sonja
Eckert, Franziska
Lohaus, Fabian
Abbasi-Senger, Nasrin
Henke, Guido
Szuecs, Marcella
Geier, Michael
Sundahl, Nora
Buergy, Daniel
Dummer, Reinhard
Guckenberger, Matthias
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2908ce3f58e34f819e02fa0ac9dff404
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2908ce3f58e34f819e02fa0ac9dff404
Other Identifiers
ISSN
1748-717X
E-ISSN
1748-717X
DOI
10.1186/s13014-020-01558-8
